The Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) is a randomized, parallel, placebo-controlled, multicenter trial designed to test the efficacy of a non-selective nonsteriodal anti-inflammatory drug and a selective COX-2 inhibitor for the prevention of Alzheimer's disease and attenuation of age related cognitive decline.  The treatment regimens, are: naproxen sodium (220 mg b.i.d.), celecoxib (200 mg b.i.d.) and matching placebos.  The trial is designed to enroll 2,625 dementia-free participants who are age 70 or older and had or have a first degree relative with Alzheimer-like dementia.  Participants will be assessed periodically for any decline in memory or cognitive function and followed for approximately 7 years. 

ADAPT datasets are available upon request. All requests must be vetted by the ADAPT Study Officers and must include an analysis plan. If the request is approved the requestor must have IRB approval to receive ADAPT data. Request can be submitted to the address provided in the "Contacts" page.

Home | Centers | Contacts | Documents | Links | Presentations | Publications